Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
Article Details
- CitationCopy to clipboard
Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
Leukemia. 2015 Sep;29(9):1939-42. doi: 10.1038/leu.2015.42. Epub 2015 Feb 13.
- PubMed ID
- 25676420 [ View in PubMed]
- Abstract
Not Available
DrugBank Data that Cites this Article
- Drugs